ImmunoPrecise Antibodies Ltd.
IPA
$0.4379
$0.01092.55%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.42M | 17.70M | 17.74M | 18.16M | 17.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.42M | 17.70M | 17.74M | 18.16M | 17.55M |
| Cost of Revenue | 8.57M | 8.80M | 9.19M | 9.23M | 8.45M |
| Gross Profit | 8.85M | 8.90M | 8.55M | 8.93M | 9.11M |
| SG&A Expenses | 13.85M | 13.98M | 13.79M | 14.15M | 13.23M |
| Depreciation & Amortization | 1.85M | 1.93M | 2.01M | 2.20M | 2.66M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.74M | 28.18M | 28.22M | 28.33M | 27.08M |
| Operating Income | -10.32M | -10.48M | -10.48M | -10.17M | -9.52M |
| Income Before Tax | -36.86M | -22.16M | -21.83M | -21.21M | -11.69M |
| Income Tax Expenses | -3.63M | -2.09M | -1.85M | -1.59M | -1.59M |
| Earnings from Continuing Operations | -33.23 | -20.07 | -19.98 | -19.62 | -10.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.23M | -20.07M | -19.98M | -19.62M | -10.11M |
| EBIT | -10.32M | -10.48M | -10.48M | -10.17M | -9.52M |
| EBITDA | -7.73M | -7.54M | -7.20M | -6.42M | -5.59M |
| EPS Basic | -1.13 | -0.75 | -0.75 | -0.75 | -0.40 |
| Normalized Basic EPS | -0.24 | -0.26 | -0.26 | -0.25 | -0.23 |
| EPS Diluted | -1.13 | -0.75 | -0.75 | -0.75 | -0.40 |
| Normalized Diluted EPS | -0.24 | -0.26 | -0.26 | -0.25 | -0.23 |
| Average Basic Shares Outstanding | 114.76M | 107.71M | 104.63M | 102.55M | 100.93M |
| Average Diluted Shares Outstanding | 114.76M | 107.71M | 104.63M | 102.55M | 100.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |